Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. - Test2 - elhamkhani - TriplyDB

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q34010378

about

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus Updates of mTOR inhibitors mTOR inhibitors in advanced renal cell carcinoma Targeting the mTOR signaling network for cancer therapy How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma Differentiating mTOR inhibitors in renal cell carcinoma Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes Individualising treatment choices in a crowded treatment algorithm Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway PI3K/PTEN signaling in angiogenesis and tumorigenesis Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.Evaluation of everolimus in renal cell cancer.Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas.Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis.A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.Everolimus for advanced pancreatic neuroendocrine tumors.

P2860

Q21198871-E434F327-7585-4DBA-AA53-0A8B50C36FCA Q21260390-7D19BE4E-A00D-4DF5-9E1B-748B3957B783 Q23923997-7677E304-0B25-482D-BF65-7CCB5D1DDE98 Q24600932-1823C594-A26F-4972-B8A0-6090EE9DBEA3 Q24607170-BBA63965-A0F1-498A-B55A-37F9D3F7E948 Q24612127-CFE6966B-1426-497F-A331-F3C9C101FB63 Q24658334-BF335FE9-8D38-407D-ABDF-FAE1B80F8F88 Q26750748-811BE399-3EE8-4768-94F0-28945A88DD27 Q26751146-B1CBF0C1-97C8-44D1-8B34-A33F72C7A57B Q26783514-A8146A11-082B-419B-8A98-DC7AC863FEBE Q26860172-6A529E55-B309-45EE-B059-17412FDFF799 Q27009257-A521B905-AE26-4D2F-BEE4-A0455B284E38 Q27023669-2490D751-851F-45C7-816A-8B4C696C0E23 Q27860948-030E8987-9918-470E-A840-2898296521DB Q28382812-6587A85D-2EE8-4C8C-A7C0-156B9E2C2693 Q28383083-1E83FBB6-A4EC-46AD-AF2D-197050EB7150 Q28546221-B9B2B7C2-119D-4510-A475-F882E2A035FC Q28765488-103F72F5-2AC3-4DE8-A8E2-61D513113581 Q33382236-74C7258A-E5D9-4ADE-972F-F6505F532C1F Q33382682-FECEC3A9-2769-4AF7-AA16-27D6F51484C6 Q33397545-3A9F80B4-76D9-4660-B6ED-2B63B26D46C4 Q33403118-03123B6B-B281-45E2-AB39-82599B4667D8 Q33404258-83B766E2-ABF4-48E3-B8A5-541AADBCB48D Q33405880-C39193B3-FDCC-4B5A-B036-2B39CC82C527 Q33407015-6C80294C-1360-4046-B81D-F3A279BEDBFA Q33407021-0365ED1A-5033-4FD6-A70E-88618FFAAC5B Q33409908-30BFDC04-1902-4B2C-96EE-B7B8E5F52EDF Q33409982-C58A222A-EED6-4F0A-91B4-674DC4F918CE Q33410691-587E2CDB-D22A-4996-AB04-653B0DB60F07 Q33414664-AFF4773B-339F-4923-B81E-CFA298A9268C Q33423855-1FC1475B-6555-489E-B648-D9DF3D46B152 Q33424413-BEAF354C-DD72-4588-ADC6-8CA03DC3EB9B Q33566872-CFE47175-4A0E-41D2-B76F-AAA4399DDBB9 Q33760578-DAD139EA-91C5-4D89-B8A2-76184323F289 Q33985467-DDF84ADC-2A6E-499A-8339-075E41642991 Q34130665-CBEEF488-1ECB-4098-A746-3BE3A42068FB Q34181598-6753832E-4D1F-44F9-9CB2-082F12754819 Q34284691-9DE94C4E-B630-45E4-B687-CB75ECD5D8D0 Q34348318-3699C159-5F33-4B1B-A47E-E32F816DC8F7 Q34399809-3D7A41D4-B904-49E2-AFE7-38181356C649

P2860

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q34010378

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@ast

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@en

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@nl

type

label

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@ast

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@en

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@nl

prefLabel

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@ast

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@en

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@nl

P1433

Q34010378-085D3494-9977-4AC0-A018-8EB2C96DB7F6

P1476

Q34010378-FE544D89-21AE-4E4F-8DD7-2B26731E781A

P2093

Q34010378-0DA82CCA-9DFD-4E54-90DD-81F2F4373D08

Q34010378-19A22204-D8A8-4BE8-8450-9BF6E9E2B537

Q34010378-19FEA22C-D103-44CD-BF02-2C9B4D6F05C5

Q34010378-2EA15E97-BF8F-47A5-8962-8920447CD95A

Q34010378-44D10685-240C-430A-8ED8-D307E53AC05A

Q34010378-517B8790-15D2-40C6-A54A-B103F210F5E1

Q34010378-5E0D69BE-2AF9-4989-84D5-48C08E65F2EC

Q34010378-83CB647D-2987-456B-A552-089A3D1F43ED

Q34010378-89A55E9F-4831-4454-AEE4-09B2F6F3E4D6

Q34010378-9E5403C8-1422-4BF0-86D6-DD297A9388B5

P304

Q34010378-13B9EE76-A59B-4E49-952D-C66926230A77

P31

Q34010378-C77C0BF7-8F79-41BB-A0DB-0230632FE5AF

P356

Q34010378-0275901C-AD73-4745-B8B0-100FA31E5028

P407

Q34010378-0D7F6C3F-D5D5-489A-97BF-6D2F302E364C

P433

Q34010378-8C41835C-8B69-41D4-8D5F-A3BE03CF2FAE

P478

Q34010378-5CF71E23-AC8C-405E-AD2C-AFEA499AB41B

P50

Q34010378-30BDDFD5-BAD3-4C2A-BCCA-FF4C993696F9

P577

Q34010378-72B82030-277D-4DA7-A277-020168225941

P5875

Q34010378-54E623B6-DEBD-41D7-913A-0D2A507F0EF1

P698

Q34010378-FF46AEDC-E529-449B-83E9-C0A188C85C8B

P921

Q34010378-9B9E9B8C-CD80-451C-84A1-AADAB2DE3775

P356

JCO.2007.14.0988

P1433

Journal of Clinical Oncology

P1476

Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.

@en

P2093

Anne O'Donnell

http://www.w3.org/2001/XMLSchema#string

Cathryn Brock

http://www.w3.org/2001/XMLSchema#string

Daniel Rea

http://www.w3.org/2001/XMLSchema#string

Eric Raymond

http://www.w3.org/2001/XMLSchema#string

Heidi A Lane

http://www.w3.org/2001/XMLSchema#string

Howard A Burris

http://www.w3.org/2001/XMLSchema#string

Ian Judson

http://www.w3.org/2001/XMLSchema#string

John M Kovarik

http://www.w3.org/2001/XMLSchema#string

Katharine Hazell

http://www.w3.org/2001/XMLSchema#string

Nicholas Shand

http://www.w3.org/2001/XMLSchema#string

P304

1588-1595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.14.0988

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Vassiliki Papadimitrakopoulou

P577

2008-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5520714

http://www.w3.org/2001/XMLSchema#string

P698

18332470

http://www.w3.org/2001/XMLSchema#string

P921